Meet with us at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco January 8-11, 201

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

The Impact of Single Indication Orphan Drugs on the Future of Rare Diseases

What is the impact of rare diseases on individuals and health care systems?

Congressionally funded report details diagnostic challenges and costs of rare diseases in the US

Diagnostics: Moving to the forefront of Global Healthcare

Economic Burden of Rare Diseases Nearly $1 Trillion

CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs

Orphan drugs account for more than half of all FDA drug approvals in 2020

Rare Disease Stakeholders: Do mRNA COV19 Vaccines Affect Eligibility to Receive Future Gene Therapy?

How do we identify and measure value for patients with rare diseases?

National Burden of Rare Disease Survey

Meet with us at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco January 8-11, 201

Recent Posts

Archive